ATG14

Across TCGA pan-cancer cohorts, ATG14 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATG14 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATG14 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATG14 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where ATG14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	1.000	0.572	.001	39	view →
LUAD	OS	Tertile	II,III,IV	0.786	1.000	.005	36	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.870	.006	13	view →
GBM	OS	Median	All	0.277	0.547	.031	3	view →
LSCC	DFS	Tertile	II,III,IV	0.958	0.860	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATG14–CCRCC (OS)

Open the CCRCC breakdown →